{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:57Z","timestamp":1792813557184,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.eururo.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T20:13:45Z","timestamp":1530216825000},"page":"455-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":296,"title":["Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial"],"prefix":"10.1016","volume":"74","author":[{"given":"Shankar","family":"Siva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarat","family":"Chander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Violet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keen Hun","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Udovicich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Selbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Goad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Foroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.06.004_bib0140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2018.06.004_bib0145","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2018.06.004_bib0150","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Euro Urol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0155","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","article-title":"Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature","volume":"67","author":"Ost","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0160","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.clon.2016.04.040","article-title":"Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences","volume":"28","author":"Ost","year":"2016","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0165","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0170","doi-asserted-by":"crossref","first-page":"E1221","DOI":"10.1097\/BRS.0b013e3181e16ae2","article-title":"A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group","volume":"35","author":"Fisher","year":"2010","journal-title":"Spine"},{"key":"10.1016\/j.eururo.2018.06.004_bib0175","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF00434743","article-title":"Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30","volume":"5","author":"Borghede","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eururo.2018.06.004_bib0180","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ejca.2008.11.013","article-title":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22","volume":"45","author":"Chow","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2018.06.004_bib0185","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2018.06.004_bib0190","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2018.06.004_bib0195","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2018.06.004_bib0200","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cncr.22799","article-title":"Interpreting clinically significant changes in patient-reported outcomes","volume":"110","author":"Ringash","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2018.06.004_bib0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Rad Oncol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0210","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.06.004_bib0215","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.06.004_bib0220","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2017.02.036","article-title":"\u201cGotta catch \u2018em all\u201d, or do we? Pokemet approach to metastatic prostate cancer","volume":"72","author":"Murphy","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0230","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.eururo.2017.06.011","article-title":"\u201cGotta catch \u2018em all\u201d or do we? Pokemet approach to metastatic prostate cancer","volume":"72","author":"Tree","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0235","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.euf.2017.07.006","article-title":"Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy","volume":"3","author":"Ponti","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2018.06.004_bib0240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.urolonc.2011.02.023","article-title":"Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer","volume":"31","author":"Muacevic","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0245","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3109\/0284186X.2013.764010","article-title":"Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and\/or distant metastases","volume":"52","author":"Schick","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0255","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is alpha\/beta for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2018.06.004_bib0260","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2018.06.004_bib0265","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clon.2007.02.007","article-title":"Is the alpha\/beta value for prostate tumours low enough to be safely used in clinical trials?","volume":"19","author":"Dasu","year":"2007","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2018.06.004_bib0270","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818304299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818304299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T13:01:46Z","timestamp":1539954106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818304299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0302283818304299"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.06.004","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}